QIAstat-Dx webinars

 

Learn about the role of multiplex testing in the COVID-19 pandemic
Title: Tackling COVID-19 through syndromic testing – QIAstat-Dx Respiratory SARS-CoV-2 Panel
Speaker: Davide Manissero, MD, MRCPCH, MSc, DTM&H, VP Head of Medical Affairs & Chief Medical Officer, Infection & Immune Diagnostics, QIAGEN

Watch the webinar

During this webinar, QIAGEN Chief Medical Officer Dr. Davide Manissero will discuss the role of multiplex respiratory PCR testing in the ongoing COVID-19 pandemic and how QIAGEN ramped up development efforts to be the first syndromic solution on the market. The importance of time to diagnosis and potential for co-infections as we approach the 2020-2021 influenza season will be discussed.

 

Learn how syndromic testing helped an Emergency Room in Paris
Title: Respiratory viruses: considerations for multiplex testing from the lab to point of care
Speaker: Dr. Benoit Visseaux, Associate Professor, Bichat Claude Bernard Hospital
This webinar discusses considerations that labs need to take into account when adopting rapid multiplex PCR testing for respiratory viruses in the clinical setting.

Watch the webinar

The development of rapid multiplex PCR tests enables the detection of almost all respiratory viruses in a few hours. These tests provide a deeper understanding of respiratory viruses’ epidemiology among children or adults, as well as community- or hospital-acquired infections. They also allow clinicians to consider viral etiology to improve isolation management, antibiotic use, or a patient’s length of stay.

While these tests offer clear benefits for some patient populations, labs looking to adopt rapid multiplex PCR testing must balance their costs against the impact on patient care.

In this webinar, Dr. Benoit Visseaux of Bichat Claude Bernard Hospital, a university hospital in Paris, shares his experience implementing multiplex PCR testing for respiratory viruses. He discusses the challenges of balancing costs with improved patient outcomes.

This study was done on the DiagCORE Analyzer using the DiagCORE Respiratory Panel V2. Now available as QIAstat-Dx in some countries. Product availability and claims may differ from country to country based on regulations and approvals. Contact your country representative for further details.
Learn how a small urban hospital offers 24/7 PCR service
Title: Syndromic testing in a small urban hospital: impact on the lab, patient outcomes, and medical decision making
Speaker: Dr. Michiel van Rijn, Clinical Microbiologist, Ikazia Hospital
This webinar discusses the implementation of a rapid 24/7 PCR service in a small urban hospital setting.

Watch the webinar

Modern PCR technologies are changing the workflow of medical microbiology laboratories, making it possible to get molecular test results within an hour instead of days to weeks. Smaller and cheaper analyzers also make multiplex PCR techniques possible for smaller laboratories without a molecular testing department.

Although the Ikazia hospital is one of the smaller hospitals in Rotterdam (360 beds), it has offered a “24/7” PCR service to its medical staff for 10 years, starting with molecular screening for methicillin-resistant Staphylococcus aureus in 2009. The hospital has expanded its portfolio in the last decade, and most recently, rolled out multiplex syndromic testing in 2018.

In this webinar, Dr. Michiel van Rijn speaks about the implementation of a rapid 24/7 PCR service in his hospital and the effects of this service on patient outcomes and clinical decision making strategies. In particular, he shares his experiences with DiagCORE syndromic testing and his expectation of further use of this technology in the future.

This study was done on the DiagCORE Analyzer using the DiagCORE Respiratory Panel V2. Now available as QIAstat-Dx in some countries. Product availability and claims may differ from country to country based on regulations and approvals. Contact your country representative for further details.
Learn about the benefits of syndromic testing for acute respiratory illness
Title: A new multiplex syndromic system for respiratory diagnosis and improved patient care
Speaker: Dr. Steve Young, Director of Research and Clinical Trials, TriCore Reference Laboratories
This webinar discusses how a new multiplexed testing system can help physicians rapidly diagnose acute respiratory infections.

Watch the webinar

Acute respiratory tract infections are caused by a wide range of viral and bacterial pathogens and may share similar clinical presentations that make it difficult for physicians to diagnose based on symptoms alone. Syndromic testing with multiplex molecular panels offers clinical labs a way to quickly distinguish between a broad array of respiratory pathogens.

In this webinar, Dr. Steve Young of Tricore Reference Laboratories presents a new technology for multiplexed respiratory testing in acutely ill patients. He shares data demonstrating the capabilities of syndromic respiratory testing as well as his impressions on the ease of doing comprehensive syndromic testing using the QIAstat-Dx Analyzer.

Product availability and claims may differ from country to country based on regulations and approvals. Contact your country representative for further details.
Learn about the role of Ct values in respiratory testing
Title: Syndromic solutions to aid therapeutic decision making for patients with respiratory infection
Speaker: Dr. Utsav Pandey, Post-Doctoral Fellow, Children’s Hospital Los Angeles
Discover Dr. Pandey’s take on how, while the clinical utility of Ct values is still being explored, including the ability to view amplification plots and Ct values for pathogens can help provide additional information.

Watch the webinar

As a fellow in a diagnostic lab, Dr. Utsav Pandey experiences firsthand the influx of respiratory testing during the flu season. He recently detailed how the lab utilizes multiplex testing on the QIAstat-Dx to address these requests.
In this recorded mini-session, hear about the lab’s QIAstat-Dx experience, including how the ability to view amplification plots and Ct values for pathogens can help provide additional information.

Watch the session highlights to hear about:
• Challenges diagnosing upper respiratory tract infections
• Syndromic testing and its potential clinical impact on patient management
• Dr. Pandey’s personal experience using the QIAstat-Dx

Be the first to know about QIAstat-Dx news and webinars

Send me updates
The QIAstat-Dx Analyzer and the QIAstat-Dx Respiratory Panel are intended for in vitro diagnostic use.

The QIAstat-Dx Respiratory SARS-CoV-2 Panel is intended for in vitro diagnostic use.

  • This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories;
  • This product has been authorized only for the detection and differentiation of nucleic acid of SARS-CoV-2 from multiple respiratory viral and bacterial organisms; and
  • This emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetics Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declarations is terminated or authorization is revoked sooner.
  • Social Sharing